Biological Modification of Arrhythmogenic Substrates by Cell-Free Therapeutics.

Abstract

Ventricular arrhythmias (VAs) represent a major cause of sudden cardiac death and afflict patients with heart failure from both ischaemic and non-ischaemic origins, and inherited cardiomyopathies. Current VA management, including anti-arrhythmic medications, autonomic modulation, implantable cardioverter-defibrillator implantation, and catheter ablation, remains suboptimal. Catheter ablation may even cause significant cardiomyocyte loss. Cell-based therapies and exosome treatment have been proposed as promising strategies to lessen cardiomyocyte death, modulate immune reaction, and reduce myocardial scarring, and, therefore, are potentially beneficial in treating VAs. In this review, we summarise the current cornerstones of VA management. We also discuss recent advances and ongoing evidence regarding cell-based and exosome therapy, with special attention to VA treatment.

• Authors: Yen-Nien Lin, Rodrigo Miguel-Dos-Santos, Eugenio Cingolani
• Journal: Heart, lung & circulation (Heart Lung Circ) Vol. 32 Issue 7 Pg. 844-851 (Jul 2023) ISSN: 1444-2892 [Electronic] Australia
• PMID: 37353457 (Publication Type: Review, Journal Article)
• Copyright: Copyright © 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Chemical References

• Anti-Arrhythmia Agents

Topics

• Humans
• Defibrillators, Implantable (adverse effects)
• Arrhythmias, Cardiac (therapy)
• Death, Sudden, Cardiac (etiology)
• Cardiomyopathies (complications)
• Anti-Arrhythmia Agents
• Catheter Ablation (adverse effects)
• Tachycardia, Ventricular (surgery)